Skip to main content

Table 3 Bladder perfusion drug selection distribution

From: Clinical application of drug sensitive gene detection in postoperative instillation for non-muscle invasive bladder cancer

 

Gemcitabine

Pirarubicin

Mitomycin

Drug sensitive group

17 (38.63%)

19 (43.18%)

8 (18.18%)

Control group

90 (35.43%)

106 (41.73%)

58 (22.83%)

χ2 value

 

0.658

 

P value

 

0.065

 
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us